JP2018516853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516853A5 JP2018516853A5 JP2017551294A JP2017551294A JP2018516853A5 JP 2018516853 A5 JP2018516853 A5 JP 2018516853A5 JP 2017551294 A JP2017551294 A JP 2017551294A JP 2017551294 A JP2017551294 A JP 2017551294A JP 2018516853 A5 JP2018516853 A5 JP 2018516853A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- antibody
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 51
- 102000036639 antigens Human genes 0.000 claims 51
- 108091007433 antigens Proteins 0.000 claims 51
- 230000004968 inflammatory condition Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 235000018417 cysteine Nutrition 0.000 claims 7
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 claims 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 150000005829 chemical entities Chemical class 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- -1 cysteine amino acids Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140913P | 2015-03-31 | 2015-03-31 | |
| US62/140,913 | 2015-03-31 | ||
| PCT/EP2016/056973 WO2016156440A1 (en) | 2015-03-31 | 2016-03-30 | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020178437A Division JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516853A JP2018516853A (ja) | 2018-06-28 |
| JP2018516853A5 true JP2018516853A5 (enExample) | 2019-05-16 |
| JP6862351B2 JP6862351B2 (ja) | 2021-04-21 |
Family
ID=55640748
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551294A Active JP6862351B2 (ja) | 2015-03-31 | 2016-03-30 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2020178437A Pending JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2023173336A Pending JP2024001166A (ja) | 2015-03-31 | 2023-10-05 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020178437A Pending JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2023173336A Pending JP2024001166A (ja) | 2015-03-31 | 2023-10-05 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10668150B2 (enExample) |
| EP (3) | EP3733701A1 (enExample) |
| JP (3) | JP6862351B2 (enExample) |
| KR (1) | KR102261618B1 (enExample) |
| CN (1) | CN108064236B (enExample) |
| AU (3) | AU2016239331C1 (enExample) |
| CA (1) | CA2982400C (enExample) |
| CL (2) | CL2017002433A1 (enExample) |
| CO (1) | CO2017010753A2 (enExample) |
| CY (1) | CY1123925T1 (enExample) |
| DK (1) | DK3277717T3 (enExample) |
| ES (1) | ES2886114T3 (enExample) |
| HR (1) | HRP20210096T1 (enExample) |
| HU (1) | HUE053097T2 (enExample) |
| IL (2) | IL254551A0 (enExample) |
| LT (1) | LT3277717T (enExample) |
| MX (1) | MX387295B (enExample) |
| MY (1) | MY190209A (enExample) |
| NZ (1) | NZ736026A (enExample) |
| PL (1) | PL3277717T3 (enExample) |
| PT (1) | PT3277717T (enExample) |
| RS (1) | RS61438B1 (enExample) |
| RU (1) | RU2736299C2 (enExample) |
| SG (1) | SG11201707593UA (enExample) |
| SI (1) | SI3277717T1 (enExample) |
| SM (1) | SMT202100086T1 (enExample) |
| TW (1) | TWI721973B (enExample) |
| WO (1) | WO2016156440A1 (enExample) |
| ZA (1) | ZA201707355B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3088517T3 (fi) | 2013-12-26 | 2023-11-30 | Mitsubishi Tanabe Pharma Corp | Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| MX2017006094A (es) | 2014-11-10 | 2017-07-19 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos. |
| SMT202100086T1 (it) * | 2015-03-31 | 2021-03-15 | Medimmune Ltd | Una nuova forma di il33, forme mutate di il33, anticorpi, saggi e metodi per usare gli stessi |
| AU2017257330A1 (en) | 2016-04-27 | 2018-10-18 | Pfizer Inc. | Anti-IL-33 antibodies, compositions, methods and uses thereof |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| PT3558369T (pt) | 2016-12-21 | 2025-05-06 | Cephalon Llc | Anticorpos que se ligam especificamente à il-15 humana e suas utilizações |
| EP3957752B1 (en) | 2017-04-13 | 2025-08-20 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| TWI850773B (zh) | 2017-08-31 | 2024-08-01 | 日商田邊三菱製藥股份有限公司 | 可溶性il-33受體的用途 |
| CN107973849B (zh) * | 2017-11-30 | 2020-07-28 | 畜科生物工程有限公司 | 一种用于增强猪疫苗免疫效果的蛋白质及其应用 |
| WO2019183375A1 (en) * | 2018-03-22 | 2019-09-26 | Eureka Therapeutics, Inc. | Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| CN112739378B (zh) * | 2018-09-14 | 2025-05-06 | 田边三菱制药株式会社 | 含有人抗il-33单克隆抗体的医药用组合物 |
| CN111434680B (zh) * | 2019-01-15 | 2021-11-23 | 南京赛新生物科技有限公司 | 一种与il33相关疾病的抗原表位肽及其应用 |
| CN111434687B (zh) * | 2019-01-15 | 2022-03-11 | 南京赛新生物科技有限公司 | 一种抗体及其应用 |
| CN112300265B (zh) * | 2019-07-29 | 2022-09-27 | 百奥赛图(北京)医药科技股份有限公司 | Il33基因人源化的非人动物的构建方法和应用 |
| CN110567861B (zh) * | 2019-09-09 | 2021-12-21 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法 |
| KR20220092927A (ko) * | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | 신장 장애를 치료하기 위한 항 il-33 치료제 |
| CA3158323A1 (en) * | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| US20230110203A1 (en) | 2020-03-13 | 2023-04-13 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| BR112022019937A2 (pt) | 2020-04-06 | 2022-12-13 | Medimmune Ltd | Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33 |
| US20230174638A1 (en) * | 2020-05-11 | 2023-06-08 | Medimmune Limited | Formulations of anti-il-33 antibodies |
| WO2021228091A1 (zh) * | 2020-05-12 | 2021-11-18 | 正大天晴药业集团股份有限公司 | St2抗原结合蛋白 |
| CN111378037B (zh) * | 2020-06-01 | 2020-09-01 | 南京诺艾新生物技术有限公司 | 一种抗hIL-33人源化单抗及其应用 |
| CN116888473A (zh) | 2021-02-18 | 2023-10-13 | 豪夫迈·罗氏有限公司 | 用于解析复杂、多步骤抗体相互作用的方法 |
| CN113234157B (zh) * | 2021-07-09 | 2021-09-21 | 上海普铭生物科技有限公司 | 亲和力成熟的人源化抗人il-33单克隆抗体及其应用 |
| CN120392998A (zh) | 2021-08-27 | 2025-08-01 | 免疫医疗有限公司 | 用抗白介素-33抗体治疗慢性阻塞性肺病 |
| EP4430072A1 (en) * | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| WO2024038187A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Assay for detection of il-33 |
| EP4573121A1 (en) | 2022-08-19 | 2025-06-25 | MedImmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| IL319071A (en) | 2022-08-19 | 2025-04-01 | Medimmune Ltd | Treatment of acute respiratory failure |
| TW202423972A (zh) | 2022-08-26 | 2024-06-16 | 英商梅迪繆思有限公司 | 使用抗介白素－３３抗體的氣喘治療 |
| AR132404A1 (es) | 2023-04-12 | 2025-06-25 | Astrazeneca Uk Ltd | Compuestos dirigidos a steap2 y uso de los mismos |
| WO2025114862A1 (en) * | 2023-11-27 | 2025-06-05 | Glaxosmithkline Intellectual Property Development Limited | Il-33 binding antibodies |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242619A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Treatment for mucus plugging |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5136964A (en) | 1989-01-19 | 1992-08-11 | Arnold J. Cook | Warning device for windsurfing craft |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0553244B8 (en) | 1990-10-05 | 2005-06-08 | Celldex Therapeutics, Inc. | Targeted immunostimulation with bispecific reagents |
| ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| DK0574395T3 (da) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
| DK0511011T3 (da) | 1991-04-26 | 1997-03-10 | Surface Active Ltd | Nye antistoffer og fremgangsmåde til anvendelse heraf |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| AU3737893A (en) | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| ATE482275T1 (de) | 1999-07-02 | 2010-10-15 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| KR101625961B1 (ko) * | 2006-09-08 | 2016-05-31 | 애브비 바하마스 리미티드 | 인터루킨-13 결합 단백질 |
| WO2008137552A2 (en) | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
| CA2686683A1 (en) * | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| WO2009055074A2 (en) | 2007-10-25 | 2009-04-30 | Wyeth | Erbb2 binding proteins and use thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| SMT202100086T1 (it) * | 2015-03-31 | 2021-03-15 | Medimmune Ltd | Una nuova forma di il33, forme mutate di il33, anticorpi, saggi e metodi per usare gli stessi |
-
2016
- 2016-03-30 SM SM20210086T patent/SMT202100086T1/it unknown
- 2016-03-30 RU RU2017134909A patent/RU2736299C2/ru active
- 2016-03-30 LT LTEP16712353.8T patent/LT3277717T/lt unknown
- 2016-03-30 CA CA2982400A patent/CA2982400C/en active Active
- 2016-03-30 PL PL16712353T patent/PL3277717T3/pl unknown
- 2016-03-30 JP JP2017551294A patent/JP6862351B2/ja active Active
- 2016-03-30 SI SI201631069T patent/SI3277717T1/sl unknown
- 2016-03-30 HR HRP20210096TT patent/HRP20210096T1/hr unknown
- 2016-03-30 HU HUE16712353A patent/HUE053097T2/hu unknown
- 2016-03-30 CN CN201680019480.3A patent/CN108064236B/zh active Active
- 2016-03-30 MX MX2017012616A patent/MX387295B/es unknown
- 2016-03-30 US US15/562,228 patent/US10668150B2/en active Active
- 2016-03-30 PT PT167123538T patent/PT3277717T/pt unknown
- 2016-03-30 MY MYPI2017703606A patent/MY190209A/en unknown
- 2016-03-30 DK DK16712353.8T patent/DK3277717T3/da active
- 2016-03-30 EP EP20169253.0A patent/EP3733701A1/en not_active Ceased
- 2016-03-30 NZ NZ736026A patent/NZ736026A/en unknown
- 2016-03-30 KR KR1020177030936A patent/KR102261618B1/ko active Active
- 2016-03-30 SG SG11201707593UA patent/SG11201707593UA/en unknown
- 2016-03-30 WO PCT/EP2016/056973 patent/WO2016156440A1/en not_active Ceased
- 2016-03-30 AU AU2016239331A patent/AU2016239331C1/en active Active
- 2016-03-30 RS RS20210171A patent/RS61438B1/sr unknown
- 2016-03-30 ES ES16712353T patent/ES2886114T3/es active Active
- 2016-03-30 EP EP23219513.1A patent/EP4374916A3/en active Pending
- 2016-03-30 EP EP16712353.8A patent/EP3277717B1/en active Active
- 2016-03-31 TW TW105110432A patent/TWI721973B/zh active
-
2017
- 2017-09-18 IL IL254551A patent/IL254551A0/en unknown
- 2017-09-27 CL CL2017002433A patent/CL2017002433A1/es unknown
- 2017-10-23 CO CONC2017/0010753A patent/CO2017010753A2/es unknown
- 2017-10-30 ZA ZA2017/07355A patent/ZA201707355B/en unknown
-
2019
- 2019-10-17 AU AU2019250213A patent/AU2019250213B2/en active Active
-
2020
- 2020-04-10 US US16/845,121 patent/US11738081B2/en active Active
- 2020-09-02 CL CL2020002269A patent/CL2020002269A1/es unknown
- 2020-10-23 JP JP2020178437A patent/JP2021038226A/ja active Pending
-
2021
- 2021-01-10 IL IL280045A patent/IL280045B/en unknown
- 2021-02-17 CY CY20211100134T patent/CY1123925T1/el unknown
- 2021-10-25 AU AU2021257881A patent/AU2021257881B2/en active Active
-
2023
- 2023-07-05 US US18/346,884 patent/US20240016929A1/en active Pending
- 2023-10-05 JP JP2023173336A patent/JP2024001166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516853A5 (enExample) | ||
| CN112574307B (zh) | 抗人Claudin18.2抗体及其应用 | |
| RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| JP2010538608A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2019054802A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2015504421A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2020524510A5 (enExample) | ||
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2011207882A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2018522888A5 (enExample) | ||
| JP2012530487A5 (enExample) | ||
| JP2017524362A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2015508056A5 (enExample) |